Bernie Sanders has health lobbyists spooked The Vermont senator is immune to their charms (Politico): The Vermont independent is set to take over the Senate’s Health, Education, Labor and Pensions Committee next month. Leading the panel gives the Medicare-for-All proponent oversight authority over some of his policy priorities — drug pricing, workers’ rights and income inequality, and student and medical debt. But Sanders’ well-chronicled antagonism toward lobbyists has some concerned they’ll be unable to blunt criticism of their clients’ profits or corporate executive salaries. They are anxious Sanders might seek to revive policies like importing drugs from Canada and other nations, an idea loathed by drugmakers. Oh, the horror! Lobbyists also worry they’ll struggle to get traction on any push to make changes to a drug discount program involving pharmaceutical companies and hospitals or revisit association health plans after a Trump-era rule around them was voided. “This will not be business as usual for K Street. It will be harder for companies to get in and make a case,” said Michaeleen Crowell, a lobbyist at lobbying and public affairs firm S-3 Group who served as Sanders’ chief of staff for more than five years. “The culture in the office is one where lobbyists are mistrusted, and they’re more likely to discount what they hear directly from companies.” I would. Wouldn’t you? “It’s not status quo … we’re going to have to be creative with patient groups to get him to listen,” said a lobbyist with health system, health insurance and pharmaceutical…